Porphyrin compounds

• US 20030017112A1
• Filed: 07/20/2001
• Published: 01/23/2003
• Est. Priority Date: 11/30/1999
• Status: Active Grant

• Current Assignee: Photochemical Co., Ltd.
• Original Assignee: Photochemical Co., Ltd.
• Inventors: Nakajima, Susumu, Sakata, Isao, Nakae, Yoshinori
• Granted Patent: US 6,746,663 B2
• Time in Patent Office: Days
• US Class Current: 424/9.61
• CPC Class Codes: A61K 41/0071 PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
• CPC Class Codes: A61K 49/0036 Porphyrins used in photodynamic therapy A61K41/0071 or A61K41/0076; used as targeting group or modifying agent for targeting a therapeutic compound A61K47/546
• CPC Class Codes: A61K 49/0052 Small organic molecules oligomers, polymers, dendrimers A61K49/0054
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: C07D 487/22 in which the condensed system contains four or more hetero rings

Abstract

The present invention provides the porphyrin compound which is used for photodynamic diagnosis and/or treatment for animals, and the photodynamic diagnostic and/or therapeutic agent for animals.

Claims

1. A porphyrin compound represented by the following formula (I):

wherein Asp represents a residue aspartic acid, or a pharmaceutically acceptable salt thereof, used for photodynamic diagnosis and/or treatment of animals.

2. The photodynamic diagnostic and/or therapeutic agent on cancers for animals comprising the porphyrin compound of formula (I) or pharmaceutically acceptable salt thereof according to claim 1 as an active ingredient.

3. The photodynamic diagnostic and/or therapeutic agent claimed in claim 2, which is used for photodynamic diagnosis and/or treatment on cancers for animals.

7. The photodynamic diagnostic and/or therapeutic agent for animals comprising the mixture substance of the porphyrin compound of formula (I) claimed in claim 1 and the porphyrin compound of formula (II) claimed in claim 2 or pharmaceutically acceptable salt thereof as an active ingredient.

8. The photodynamic diagnostic and/or therapeutic agent claimed in claim 7, which is used for photodynamic diagnosis and/or treatment on cancers for animals.

4. A porphyrin compound represented by the following formula (II):

wherein Asp represents a residue of aspartic acid, or a pharmaceutically acceptable salt thereof, used for photodynamic diagnosis and/or treatment of animals.

5. The photodynamic diagnostic and/or therapeutic agent on cancers for animals comprising the porphyrin compound of formula (II) or pharmaceutically acceptable salt thereof according to claim 4 as an active ingredient.

6. The photodynamic diagnostic and/or therapeutic agent claimed in claim 4, which is used for photodynamic diagnosis and/or treatment on cancers for animals.